| Literature DB >> 32117362 |
Lixia Yuan1, Runzhi Li2.
Abstract
Camelina sativa (L.) Crantz is an important Brassicaceae oil crop with a number of excellent agronomic traits including low water and fertilizer input, strong adaptation and resistance. Furthermore, its short life cycle and easy genetic transformation, combined with available data of genome and other "-omics" have enabled camelina as a model oil plant to study lipid metabolism regulation and genetic improvement. Particularly, camelina is capable of rapid metabolic engineering to synthesize and accumulate high levels of unusual fatty acids and modified oils in seeds, which are more stable and environmentally friendly. Such engineered camelina oils have been increasingly used as the super resource for edible oil, health-promoting food and medicine, biofuel oil and high-valued chemical production. In this review, we mainly highlight the latest advance in metabolic engineering towards the predictive manipulation of metabolism for commercial production of desirable bio-based products using camelina as an ideal platform. Moreover, we deeply analysis camelina seed metabolic engineering strategy and its promising achievements by describing the metabolic assembly of biosynthesis pathways for acetyl glycerides, hydroxylated fatty acids, medium-chain fatty acids, ω-3 long-chain polyunsaturated fatty acids, palmitoleic acid (ω-7) and other high-value oils. Future prospects are discussed, with a focus on the cutting-edge techniques in camelina such as genome editing application, fine directed manipulation of metabolism and future outlook for camelina industry development.Entities:
Keywords: Camelina sativa (L.) Crantz; designed oil; fatty acids; metabolic engineering; model oilseed
Year: 2020 PMID: 32117362 PMCID: PMC7028685 DOI: 10.3389/fpls.2020.00011
Source DB: PubMed Journal: Front Plant Sci ISSN: 1664-462X Impact factor: 5.753
Lipid metabolic engineering in seeds of Camelina sativa in recent years.
| Target lipid | Target gene | Manipulation | Phenotype | Reference |
|---|---|---|---|---|
| Cyclopropane fatty acids (CPAs) | Lychee phosphatidylcholine: diacylglycerol cholinephosphotransferase (LcPDCT) and Escherichia coli cyclopropane synthase (EcCPS) | Co-overexpression | 50% increase of CPAs |
|
| Medium-chain FA (MCFA)-containing acetyl-TAGs (MCFA-AcTAGs) | EaDAcT, ChFatB2, cpFatB2, UcFatB1, CnLPAAT, CsDGAT1, and CsPDAT1 | Co-expression of EaDAcT with one or two of ChFatB2, cpFatB2, UcFatB1, CnLPAAT, plus combination with CsDGAT1-RNAi and CsPDAT1-RNAi | Significant increased levels of MCFA-AcTAGs, MCFA-AcTAGs was up to 77% more in the best lines |
|
| Acetyl-TAGs | EaDAcT, and CsDGAT1 | Co-expression of EaDAcT together with RNAi suppression of CsDGAT1 | AcTAGs with a 2-fold reduction in very long chain fatty acids was up to 85 mol % in the field-grown transgenic line |
|
| Saturated FAs, | Fatty acyl-ACP thioesterases | Artificial microRNA mediated CsFATB gene suppression (amiFATB) | 35% reduction of total saturated FAs and an increase of oleic acid in seed oil |
|
| Hydroxy fatty acids (HFAs) | Lesquerella ( | Co-expression of LfKCS3 and RcFAH12 | Increased HFAs higher than that in the transgenics expressing RcFAH12 alone |
|
| C(20-C24 very long chain FAs (VLCFAs,), | Fatty acid elongase1 (FAE1) | Knocking out three CsFAE1 alleles by CRISPR technology with an egg cell-specific Cas9 expression | Reduction of VLCFAs from over 22% to less than 2% of total FAs and concomitant increase of C18 unsaturated FAs |
|
| Hydroxy fatty acids (HFAs) | Phospholipase C-like protein (RcPLCL1) and fatty acid hydroxylase (RcFAH12) from | Seed-specific coexpression of RcPLCL1 and RcFAH12 | HFAs was increased to 24% of total FAs |
|
| Oleic acid | Fatty acid desaturase 2 (FAD2) | Knockout of all three CsFAD2s by CRISPR/Cas9 | Oleic acid level was increased from 16% to >50% and total MUSFA |
|
| Oleic acid | Fatty acid desaturase2 (FAD2) | Knockout of three, two, and an isologous CsFAD2 by CRISPR/Cas9 | Oleic acid level was increased from 10% to 62% of total FAs in different allelic combinations |
|
| Linolenic(18:3) and | Two Arabidopsis phospholipase Dζ genes (AtPLDζ1 and AtPLDζ2 ) | Co-expression of AtPLDζ1 and AtPLDζ2 | TAG was increased by 2% to 3% more compared to wild type. Increase of 18:3 and (20:1 FAs was concurrent with decrease of other FAs |
|
| Oil and seed yields | Arabidopsis diacylglycerol acyltransferase1 (AtDGAT1) and a yeast cytosolic glycerol-3-phosphate dehydrogenase (ScGPD1) | Seed-specific coexpression of AtDGAT and ScGPD1 | The transgenic seeds showed up to 13% higher seed oil content and up to 52% increase in seed mass, with decreased 18:1 level |
|
| Linolenic(18:3) and linoleic acid | CsPDAT1 and CsDAT1 | Overexpression of CsPDAT; silencing of CsDGAT1 by amiRNA | Levels of 18:3 was up to 56 mol% of total FAs in CsDGAT1-silenced lines; |
|
| α-linolenic acid, | microRNA167A (miR167A), camelina fatty acid desaturase3 (CsFAD3) and, auxin response factor 8 (CsARF8) | Seed-specific expression of miR167 which suppresses CsARF8 and then mediates transcriptional cascade for CsFAD3 suppression via the ABI3-bZIP67 pathway | Decrease of α-linolenic acid and concomitant increase of linoleic acid , and also increased seed size |
|
| ω-3 long chain PUFAs, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) | Δ6-desaturase from | Assembly of EPA and DHA pathway by seed-specific expression 5 genes (PSE1, TcΔ5, OtΔ6, Hpω3, and PsΔ12) and 7 genes (PSE1, TcΔ5, OtΔ6, Piω3, PsΔ12, OtElo5 and EhΔ4), respectively | EPA content was 16.2-17.2 % of total FAs in the 5-gene transgenics; EPA and DHA levels were 4.3-4.9% and 4.0% of total FAs in the 7-gene transgenics, respectively |
|
| ω-3 long chain PUFAs, EPA and eicosatetraenoic acid (ETA) | Δ9-elongase from | Assembly of Δ9-alternative pathway for ω-3 long chain PUFAs biosynthesis by seed-specific expression 6 genes (EhElo9, IsoElo9, PsΔ8, EhΔ5, Piω3 and PsΔ12) | Mean EPA levels in T3 |
|
| Medium-chain, saturated fatty acids (MCSFAs) | 12:0-acyl-carrier thioesterase (UcFATB1) from | Seed-specific expression of UcFATB1 alone or together with CsKASII RNAi | Level of laurate (12:0) and myristate (14:0) were up to 40% of the seed oil in UcFATB1 transgenics; Level of 16:0 was increased from 7.5% up to 28.5% of total FAs in KASII-RNAi lines. Level of MCSFAs (12:0, 14:0 and 16:0) was up to 30% of the co-transformed seeds |
|
| Medium-chain fatty acids (MCFAs; 8:0-14:0) | CpuFatB3 and CpuFatB4 from | Seed-specific expression of each of those FatBs; Co-expression of two or three of those FatBs; Co-expression of FatB and CnLPAT | MCFAs were greatly accumulated in the individual FatB transgenics and much high levels occurred in coexpression lines |
|
| Novel wax esters (WEs) | Acyl-ACP thioesterases (Thio), a fatty acid hydroxylase (FAH), | Co-expression of WS and FAR; | WEs with different compositions were produced in the transgenic seeds of FAR, WS and Thio; WEs with reduced chain lengths were produced in coexpression lines of MaFAR, MhWS, and Thio |
|
| Oleyl oleate wax esters (Oleyl oleate WEs) | Co-expression of ScWS and MaFAR | Levels of oleyl oleate WEs were 21% of the seed oil TAGs in the coexpression lines of MaFAR and ScWS |
| |
| Nervonic acid | β-ketoacyl-CoA synthase (LaKCS) from | Seed-specific expressing of LaKCS ( | Nervonic acid in seed oil increased from null to 6-12% in |
|
| Seed oil | A patatin-related phospholipase AIIIδ (pPLAIIIδ) from Arabidopsis | Constitutive or seed-specific expression of pPLAIIIδ ( | Seed oil increased greatly and cellulose reduced in |
|
| ω-7 FAs (16:1Δ9, 18:1Δ11, 20:1Δ13) | A mutant Δ9-acyl-ACP (Δ9DES1), a 16:0-specific acyl-CoA desaturase (Δ9DES2), 3-keto-acyl-ACP synthase II (KASII) and FatB 16:0-ACP thioesterase (FatB) | Seed-specific co-expression of Δ9DES1and Δ9DES2 ( | ω-7 FAs was increased to 17% in |
|
| DHA | Δ;5-desaturase (Δ5D), Δ6-elongase (Δ5E), Δ6D, Δ6E, Δ4D, Δ12D , and ω3-desaturase (ω3D) | Overexpression of the 7 gens(Δ4D, Δ5D, Δ5E, Δ6D, Δ6E, Δ12D and ω3D) | levels of DHA was up to > 12% with very high ω3: ω6 ratios in transgenic seeds |
|
| Cuticular wax | Arabidopsis MYB96 (AtMYB96) | Overexpression of AtMYB96 driven by CaMV35S promoter | Significant increase of epicuticular wax crystals and total wax loads on the surfaces of transgenic leaves |
|
Figure 1Strategy for redesigning biosynthesis of acetyl-TAG in C. sativa seeds. DAG, Diacylglycerol; lcTAG, Long-chain Triacylglycerol; acTAG, Acetyl Triacylglycerol; DGAT, Diacylglycerol acyltransferases; EaDAcT, Euonymus alatus diacylglycerol acetyl‐CoA transferase.
Figure 2Schematic diagram showing the key steps of de novo synthesis of fatty acids and triacylgltcerols with main modified targets for medium-chain fatty acid production in plant seeds. FAS; Fatty acid synthase; FatA, Fatty acid thioesterase A; FatB, Fatty acid thioesterase B; KASII, β‐ketoacyl‐ACP synthase II; DAG, Diacylglycerol; DGAT, Diacylglycerol acyltransferases; TAG, Triacylglycerol; PDAT, Phospholipid diacylglycerol acyltransferase; GPAT, glycerol-3-phosphate acyltransferase; LPAT, Lysophosphatidic acid acyltransferase; PDH, Pyruvate dehydrogenase; ACC, Acetyl-CoA carboxylase; Pyr, Pyruvic acid.
Figure 3Strategy to assembly biosynthesis of ω-3 LC-PUFAs in C. sativa seeds. Δ3 Des, Δ3-desaturase; Δ4 Des, Δ4-desaturase; Δ5 Des, Δ5-desaturase; Δ6 Des, Δ6 -desaturase; Δ8 Des, Δ8-desaturase; Δ5 Elo, Δ5-elongase; Δ6 Elo, Δ6-elongase; Δ9 Elo, Δ9-elongase; ALA,α-Linolenic acid; ARA, Arachidonic acid; DGLA, Dihomo-γ-linolenic acid; DHA, Docosahexaenoic acid; DPA, Docosapentaenoic acid; DTA, Adrenic acid; EDA, Eicosadienoic acid; EPA, Eicosapentaenoic acid; ERA, Eicosatrienoic acid; ETA, Eicosatetraenoic acid; GLA, γ-Linolenic acid; LA, Linoleic acid; SDA, Stearidonic acid; TAG, Triacylglycerol. (The figure is modified according to Ruiz-Lopez et al., 2015.)
Figure 4Strategy redesigning biosynthetic pathways for ω-7 FAs production in common oil seeds. ER, Endoplasmic reticulum; FAS, Fatty acid synthase; FatA, Fatty acid thioesterase A; FatB, Fatty acid thioesterase B; FAE, Fatty acid elongase; KASII, β‐ketoacyl‐ACP synthase II; TAG, Triacylglycerol. Green arrows indicate up-regulation, red arrows indicate down-regulation; ① and ② are to silence KASII and FatB, respectively, to increase pool sizes of 16:0-ACP in plastid to provide more substrates fo16:0-ACP Δ9-desaturase; ③ is to introduce a plastid-localized acyl-ACP Δ9-desaturase with high 16:0-ACP activity; ④ is to introduce an ER-localized 16:0-CoA-specific Δ9-desaturase to catalyze 16:0-CoA into 16:1-CoA in cytoplasm.